CADL

Candel Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 4/10
  • Value↑ 5/10
Candel Therapeutics sales and earnings growth
CADL Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 24.43%
  • FCF Y/Y↓ -79.93%
Candel Therapeutics gross and profit margin trends
CADL Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -230.73%
Candel Therapeutics net debt vs free cash flow
CADL Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -15.1

Candel Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks